Co-formulated elvitegravir / cobicistat / emtricitabine / tenofovir (QUAD)

Source: London New Drugs Group Area: Evidence > Drug Specific Reviews The new QUAD tablet consists of three antiretrovirals, elvitegravir, emtricitabine and tenofovir, and a booster, cobicistat. UK launch is anticipated in Q2 2013, subject to EU approval. It is the first single-tablet regimen to combine a once-daily integrase inhibitor (elvitegravir) which is boosted by a first-in-class pharmacoenhancer (cobicistat), plus a preferred backbone of emtricitabine and tenofovir. Two phase III studies have been carried out:  Study 102 and 103, comparing QUAD to Atripla (Study 102) and to atazanavir/ritonavir plus emtricitabine and tenofovir.  This review evaluates the clinical data supporting the safety and efficacy of QUAD.
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news